Compare ELMD & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELMD | SGMT |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.1M | 169.4M |
| IPO Year | 2010 | 2021 |
| Metric | ELMD | SGMT |
|---|---|---|
| Price | $38.41 | $7.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $36.00 | $26.13 |
| AVG Volume (30 Days) | 127.8K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $54,716,000.00 | $2,000,000.00 |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $41.96 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $17.73 | $4.50 |
| 52 Week High | $47.40 | $10.46 |
| Indicator | ELMD | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 47.42 |
| Support Level | $35.61 | $7.04 |
| Resistance Level | $40.00 | $7.39 |
| Average True Range (ATR) | 2.17 | 0.44 |
| MACD | -1.01 | -0.08 |
| Stochastic Oscillator | 9.48 | 21.77 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.